Wedbush Comments on Voyager Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:VYGR)

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Wedbush lowered their Q3 2024 EPS estimates for Voyager Therapeutics in a report issued on Wednesday, August 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.60) for the quarter, down from their prior estimate of ($0.51). Wedbush has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.39) per share. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.61) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.79) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.59%. The firm had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter last year, the business earned ($0.51) earnings per share.

A number of other analysts have also issued reports on VYGR. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Oppenheimer restated an “outperform” rating and set a $18.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.83.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $6.92 on Friday. Voyager Therapeutics has a 1 year low of $6.06 and a 1 year high of $11.72. The firm’s 50 day moving average price is $8.33 and its 200 day moving average price is $8.39. The firm has a market cap of $376.38 million, a P/E ratio of -138.37 and a beta of 0.96.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA raised its stake in shares of Voyager Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 143,523 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,816 shares during the period. Federated Hermes Inc. raised its stake in shares of Voyager Therapeutics by 0.5% in the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after acquiring an additional 2,638 shares during the period. American Century Companies Inc. raised its stake in shares of Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after acquiring an additional 249,659 shares during the period. ClariVest Asset Management LLC raised its stake in shares of Voyager Therapeutics by 2.7% in the 2nd quarter. ClariVest Asset Management LLC now owns 102,822 shares of the company’s stock valued at $813,000 after acquiring an additional 2,699 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.